NCT05408221View on ClinicalTrials.gov

the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

576

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Rulonilimab+Lenvatinib

Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily

DRUG

Rulonilimab placebo +Lenvatinib

Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily

Trial Locations (5)

100029

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Unknown

RECRUITING

Huizhou Central People's Hospital, Guandong

RECRUITING

Jinan Central Hospital, Shandong

RECRUITING

Linyi Cancer Hospital, Shandong

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen

All Listed Sponsors
lead

Shandong New Time Pharmaceutical Co., LTD

INDUSTRY